期刊文献+

新一代广谱抗生素替加环素的专利解析

Patent Analysis of a New Generation of Broad Spectrum Antibiotics Tigecycline
下载PDF
导出
摘要 替加环素是美国惠氏制药公司研发的新一代广谱抗生素药物,替加环素是目前治疗超级细菌最新的抗生素品种。本文从原研企业惠氏制药公司的替加环素专利策略、替加环素专利申请现状角度出发,对替加环素相关技术进行了解析,为国内的制药企业制定专利战略提供参考。 Tigecycline is a new generation broad-spectrum antibiotic drug developed by Wyeth Pharmaceuticals Inc. Tigecycline is the latest antibiotic variety currently used in the treatment of superbugs. This article analyzed Tigecycline-related technology through two aspects: the original research company Wyeth pharmaceutical company 's strategy of Tigecycline patent application、current situation of Tigecycline patent. This will provide the sake of offering consult to the domestic pharmaceutical enterprises on patent countermeasures.
作者 周静 范鑫鑫 Zhou Jing;Fan Xinxin(Patent Examination Cooperation(Hubei)Center of the Patent Office,SIPO,Wuhan 430000,China;Patent Examination Cooperation(Beijing)Center of the Patent Office,SIPO,Beijing 100000,China)
出处 《山东化工》 CAS 2018年第9期51-52,共2页 Shandong Chemical Industry
关键词 抗生素 替加环素 专利分析 antibiotics Tigecycline patent countermeasure
  • 相关文献

参考文献4

二级参考文献40

  • 1熊剑文,裴云,冯瑞祥,李亚舒,杨成芳.耐甲氧西林葡萄球菌的耐药性监测[J].南京军医学院学报,2003,25(4):223-225. 被引量:1
  • 2朱德妹,汪复,张婴元.2003年上海地区细菌耐药性监测[J].中国抗感染化疗杂志,2005,5(1):4-12. 被引量:147
  • 3张致平.抗耐药菌药物研究进展[J].中国抗生素杂志,2005,30(7):430-440. 被引量:12
  • 4朱德妹,汪复,张婴元.2004年上海地区细菌耐药性监测[J].中国抗感染化疗杂志,2005,5(4):195-200. 被引量:227
  • 5Wyeth Pharmaceuticals Inc. Tygacil Product Insert Philadelphia, PA, USA[EB/OL]. http://www, tygacil, com, 2006 12 -19.
  • 6Bauer G, Berens C, Projan SJ, et al. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethysulphate and drug directed Fe^2+ cleavage of 16S rRNA[J]. J Antimicrob Chemother, 2004, 53(4) :592-599.
  • 7Rice LB. Challenges in identifying new antimicrobial agents effective for treating infection with Acinetobaeter baumannii and Pseudomonas aeruginosa [J]. Clin infect Dis,2006, 43 (Suppl 2) : S100 S105.
  • 8Kelesidis T, Karageorgopoulos DE, Kelesidis I, et al. Tigecycline for the treatment of multidrug resistant Enterobacteriaceae : a systematic review of the evidence from microbiological and clinical studies[J]. J Antimicrob Chemother, 2008, 62(5) :895- 904.
  • 9Baudry PJ, Nichol K, DeCorby M, et al. Comparison of antimicrobial resistance profiles among extended-spectrum-betalactamase producing and acquired AmpC beta lactanase-producing Escherichia coli isolates from Canadian intensive care units[J]. AntimicrobAgentsChemother, 2008, 52(5):1846-1849.
  • 10Castanheira M, Sader HS, Deshpande LM, et al. Antimierobial activities of tigecycline and other broad speetrum antimicrobials tested against serine earbapenemase and metallo-β- laetamase-producing Enterobacteriaceae: Report from the SENTRY Antimicrobial Surveillance Program[J]. Antimicrob Agents Chemother, 2008, 52(2) :570- 573.

共引文献150

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部